



Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in September

September 6, 2022

SEATTLE, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that the Company will participate in two upcoming investor conferences in September:

- **H.C. Wainwright 24th Annual Global Investment Conference:** Adrian Adams, Chairman and Chief Executive Officer, will participate in a fireside chat on Tuesday, September 13, 2022 at 5:00 p.m. ET in New York, NY.
- **Guggenheim Nantucket Therapeutics Conference:** John Leaman, M.D., Chief Financial and Business Officer, will participate in a fireside chat on Thursday, September 29, 2022 at 11:00 a.m. ET in Nantucket, MA.

A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at <https://investors.impelpharma.com/>. A replay of the presentation will be available on the website for 90 days.

About Impel Pharmaceuticals

Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary POD[®] technology with well-established therapeutics. In addition to Trudhesa[®] nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism.

For additional information about Impel, please visit www.ImpelPharma.com

Contact:

Media Relations:

Melyssa Weible
Elixir Health Public Relations
Phone: (1) 386-366-0616
Email: mweible@elixirhealthpr.com

Investor Relations

Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com